Moreover, the incidence of grade 4 neutropenia significantly decreased after the administration of G-CSF (before G-CSF: 86.1%, n = 93; after G-CSF: 14.8%, n = 16, p < 0.01). This evidence concerns the gene CSF3 and neutropenia.